Search
The Inventor
Dr. Jonathan Wall is the director or the Preclinical and Diagnostic Molecular Imaging Laboratory and a professor in the Department of Medicine Human Immunology and Cancer Program at the University of Tennessee. He received Ph.D. degree from University of Essex (United Kingdom). After working as a postdoctoral researcher at the University of Tennessee Medical Center Human Immunology & Cancer Program, he joined the university as an assistantprofessor in 1997. Dr. Wall's work is dedicated to the study of disease and the development and evaluation of novel treatments and diagnostic techniques.
Contact
The University of Tennessee Research Foundation (UTRF) is a non-profit corporation responsible for commercializing University of Tennessee technologies and for supporting University research. UTRF is seeking parties interested in learning more about this technology and in exploring possible research and/or commercialization arrangements.
If after reviewing this abstract you would like further information, please phone us at 865.974.1882 or send an email to utrfinnovations@tennessee.edu and reference PD 06082. We will get in touch with you as soon as possible to make the appropriate arrangements, including discussions with the inventor. We will also be glad to discuss possible avenues for commercialization of this technology or answer any questions you may have regarding UTRF.
A Diagnostic and Therapeutic Agent for Epithelial Cancers
Health Sciences Technologies for Licensing
The Technology
Researchers at the University of Tennessee have discovered that the odontogenic ameloblastassociated protein (ODAM) can be detected in human epithelial cancers, including those of breast, lung, and gastric origin as well as primary melanoma. The inventors also discovered that ODAMreactive antibodies are present in the serum of patients suffering from these same cancers. The research group of Dan Kestler has generated antibodies that can be used not only as research reagents but also may be developed into diagnostic kits for clinical monitoring of patients with melanoma or breast cancer. An ELISA assay has been developed that has potential for detecting cancer-related proteins in the blood of patients with breast cancer.
Benefits
- A sensitive diagnostic and prognostic biomarker for human epithelial cancers.
- A specific therapeutic target for human epithelial cancers
Patents
- Patent pending